
NICE has published final guidance today which rejects tafamidis, also known as Vyndaqel, for treating rare heart condition transthyretin amyloidosis …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

